Investigational drug · Phase 2
Autologous HB-adMSCs
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Traumatic Brain Injury, Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis.
Phase 2Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
22
Any phase or sponsor naming "Autologous HB-adMSCs"
First trial start
2024
Apr 16, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Autologous HB-adMSCs", any sponsor or status.
Conditions studied
As listed on its trial records.
- Traumatic Brain Injury
- Relapsing Remitting Multiple Sclerosis (RRMS)
- Multiple Sclerosis
Approved drugs for the same conditions: Multiple sclerosis · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Autologous HB-adMSCs" as an intervention, largest first.
Hope Biosciences Research FoundationIndustry
NCT04349631 · 51 participants · Start Apr 20, 2020 · Primary completion Nov 25, 2020
Drug: HB-adMSCs · For: COVID-19
Sites: Sugar Land, Texas
Hope Biosciences LLCIndustry
NCT05951777 · 51 participants (planned) · Start Apr 16, 2024 · Primary completion Dec 2027
Drug: Autologous HB-adMSCs; Normal Saline · For: Traumatic Brain Injury
Sites: Houston, Texas; San Antonio, Texas
Hope Biosciences LLCIndustry
NCT04063215 · 24 participants · Start Jan 1, 2020 · Primary completion Oct 25, 2024
Drug: HB-adMSCs · For: Traumatic Brain Injury
Sites: Houston, Texas
Hope Biosciences Research FoundationIndustry
NCT05116540 · 24 participants · Start Nov 24, 2021 · Primary completion Jun 4, 2024
Drug: HB-adMSCs; Placebo · For: Multiple Sclerosis
Sites: Sugar Land, Texas
Hope Biosciences Research FoundationIndustry
NCT04928287 · 24 participants · Start Jun 28, 2021 · Primary completion Feb 6, 2023
Drug: HB-adMSCs · For: Parkinson Disease
Sites: Sugar Land, Texas
Hope Biosciences LLCIndustry
NCT03691909 · 15 participants · Start Sep 25, 2018 · Primary completion Aug 17, 2020
Drug: HB-adMSCs · For: Rheumatoid Arthritis
Sites: Pasadena, Texas
- "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"Active, not recruiting
Hope Biosciences Research FoundationIndustry
NCT06800404 · 10 participants · Start May 2, 2025 · Primary completion Jan 2027
Drug: Autologous HB-adMSCs · For: Relapsing Remitting Multiple Sclerosis (RRMS); Multiple Sclerosis
Sites: Sugar Land, Texas
Hope Biosciences LLCIndustry
NCT04228666 · 0 participants · Start Mar 1, 2020 · Primary completion Feb 1, 2022
Drug: HB-adMSCs · For: Alzheimer Disease
Sites: Houston, Texas
- Individual Patient Expanded Access IND for the Treatment of StrokeNo longer available
Hope Biosciences Research FoundationIndustry
NCT04907188
Drug: HB-adMSCs · For: Stroke; Stroke, Ischemic
Sites: Sugar Land, Texas
- Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)No longer available
Hope Biosciences Research FoundationIndustry
NCT04907175
Drug: HB-adMSCs · For: System; Lupus Erythematosus
Sites: Sugar Land, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Evaluation of Multiple Intravenous Infusions of Autologous Adipose-Derived Mesenchymal Stem Cells in Parkinson's Disease: A Randomized, Double-Blind Clinical Trial.
Vij R, Kim H, Park H, et al. · Parkinsons Dis 2026
- Safety and efficacy of adipose-derived mesenchymal stem cell therapy in elderly Parkinson's disease patients: an intermediate-size expanded access program.
Vij R, Kim H, Park H, et al. · Cytotherapy 2025
- Functional recovery of a 41-year-old quadriplegic spinal cord injury patient following multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells: a case report.
Vij R, Kim H, Park H, et al. · Front Transplant 2023
- Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program.
Vij R, Kim H, Park H, et al. · Stem Cell Res Ther 2023
Also in development for Traumatic Brain Injury
- SovateltideIRL-1620, PMZ-1620Phase 32 trials
Pharmazz, Inc. · Traumatic Brain Injury, Acute Ischemic Stroke, Cerebral Stroke
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.